Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T8EL
|
|||
| Former ID |
DIB014709
|
|||
| Drug Name |
AHL
|
|||
| Synonyms |
AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark
Click to Show/Hide
|
|||
| Drug Type |
siRNA drug
|
|||
| Indication | Hearing disorder [ICD-11: AB50-AB57] | Investigative | [1] | |
| Company |
Quark Pharmaceuticals Inc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012 Jan 15;118(2):418-27. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.